Lawyers and Settlements
Home Page >> Hot Legal Issues >> Invokana Linked with Cardiovascular Injuries and Kidney Failure

Invokana Linked with Cardiovascular Injuries and Kidney Failure



Invokana lawsuits have been filed against Janssen Pharmaceuticals alleging Invokana side effects include an increased risk of kidney problems and cardiovascular problems. Additionally, the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have issued warnings about kidney problems and diabetic ketoacidosis—both of which are serious conditions—potentially linked to Invokana use.

En Español [INVOKANA]

FREE CASE EVALUATION

Send your Invokana claim to a lawyer who will review your claim at NO COST or obligation.Get Legal Help Now

Invokana

Invokana (canagliflozin), is a type 2 diabetes medication and is in a class of drugs known as SGLT2 inhibitors. It works by causing the kidneys to remove sugar from the blood via urine and was first approved by the US Food and Drug Administration (FDA) in 2013. Some diabetes patients may be prescribed Invokamet, which is a diabetes medication combining Invokana with metformin hydrochloride (Glucophage).

Other drugs in the SGLT2 class include dapagliflozin (Forxiga) and empagliflozin (Jardiance), Xigduo XR (dapagliflozin and metformin extended-release) and Glyxambi (empagliflozin and linagliptin).

Invokana Lawsuits

Invokana lawsuits have now been filed against Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson, alleging patients suffered serious side effects as a result of the use of Invokana. One such lawsuit (Maddox v. Janssen Pharmaceuticals, et al, case number; 2:16-cv-01189) alleges patients who were prescribed Invokana "have suffered and may continue to suffer severe and permanent personal injuries, including diabetic ketoacidosis, stroke, heart attack, and severe kidney damage."

Maddox's lawsuit alleges the defendants knew or should have known about the risks but failed to adequately warn patients, putting them at risk of diabetic ketoacidosis, cardiovascular problems and kidney damage. Specifically, Maddox argues he developed ketoacidosis and kidney damage less than a year after starting Invokana treatment.

Invokana Ketoacidosis

In May 2015, the FDA warned that Invokana was linked to ketoacidosis, a serious condition in which the body produces high levels of ketones. Patients were warned to watch for signs of ketoacidosis, including difficulty breathing, nausea, vomiting, abdominal pain, confusion and unusual fatigue or sleepiness and seek medical attention if any signs of ketoacidosis occur.

According to the Mayo Clinic, DKA symptoms may also include excessive thirst, frequent urination and even fruity-scented breath. Diabetes patients can typically recognize signs of diabetic ketoacidosis via home blood and urine tests that indicate high blood sugar levels (hyperglycemia) and/or high ketone levels.

The FDA's warning was based on its Adverse Event Reporting System (FAERS), which contained 20 cases of acidosis, ketoacidosis or ketosis in patients treated with SGLT2 inhibitors between March 2013 and June 2014. FDA notes that more Invokana FAERS reports have been received since June 2014. All patients reportedly required hospitalization.

Diabetic ketoacidosis is a serious condition that occurs when insulin levels are too low resulting in excessively high blood sugar levels. The body then burns fat for fuel, resulting in ketones building up, which upsets the blood's chemical balance. A person experiencing DKA may require emergency care and hospitalization to treat the ketoacidosis.

Invokana Adverse Reactions

In March 2015, the FDA requested an update to Invokana's label to warn about the risk of genital mycotic infections (yeast infections) in both males and females. A study presented at the American Diabetes Association (ADA) 2013 Scientific Sessions suggested 10 percent of women taking Invokana experienced a yeast infection compared with three percent of women who took a placebo.

Invokana has reportedly been linked to an increased risk of kidney problems. In 2015, the Institute for Safe Medication Practices warned in its quarterly report that it had identified 457 serious adverse event reports, including kidney failure or impairment, dehydration and fluid imbalances, kidney stones, urinary tract infections and abnormal weight loss.

On February 12, 2016, the European Medicines Agency (EMA) issued recommendations concerning SGLT2 Inhibitors. The agency warned that patients taking such medications should contact healthcare professionals immediately and treatment should be stopped if diabetic ketoacidosis is confirmed.

SGLT2 Inhibitor FDA Warning

In addition to Invokana and Invokamet, the FDA has also issued a warning about SGLT2 inhibitors potentially leading to DKA. The FDA is investigating type 2 diabetes medications including dapagliflozin (Forxiga) and empagliflozin (Jardiance). Additionally, two other SGLT2 inhibitors, Xigduo XR (dapagliflozin and metformin extended-release) and Glyxambi (empagliflozin and linagliptin) are also being investigated.

Invokana Lawsuits

Attorneys are investigating possible Invokana lawsuits. Patients who have suffered adverse events after using Invokana—or people whose loved ones died after suffering an adverse event—may be eligible to file a lawsuit. If you or a loved one has suffered damages or injuries due to Invokana, please click the link below and your complaint will be sent to a Drug and Medical Device lawyer who will evaluate your claim at no cost or obligation.
Last updated on

INVOKANA LEGAL ARTICLES AND INTERVIEWS

New Invokana Research (Funded by Manufacturer) Disputes Earlier Studies Showing Amputation Risk
New Invokana Research (Funded by Manufacturer) Disputes Earlier Studies Showing Amputation Risk
October 2, 2017
Washington, DC: Despite exhaustive studies that found an increased risk of amputation among Invokana diabetes patients, Janssen Pharmaceuticals has published its own version of research [READ MORE]

Janumet Patient Felled by Cancer of the Pancreas in 2012
Janumet Patient Felled by Cancer of the Pancreas in 2012
August 22, 2017
Los Angeles, CA: When Janumet (sitagliptin and metformin combined) was approved by the US Food and Drug Administration (FDA) in 2007, the type 2 diabetes drug was within five years of achieving sales of $1.7 Billion. That year, when Janumet hit blockbuster status by 2012, the parent drug of Janumet – Januvia – earned $4 Billion for manufacturer Merck & Co. Januvia has been associated with Januvia side effects, and has resulted in Januvia cancer lawsuits [READ MORE]

Are Risk of Invokana and Invokamet Bone Fractures a Sign of Fractured Regulations?
Are Risk of Invokana and Invokamet Bone Fractures a Sign of Fractured Regulations?
August 8, 2017
Washington, DC: A drug indicated for the treatment of type 2 diabetes already carries warnings for compelling adverse reactions including a heightened risk for lower limb amputations, kidney failure, diabetic ketoacidosis and cardiovascular injuries. To that end, the FDA warns of fracture risk with Invokana and Invokamet. Yet in spite of such serious side effects associated with Invokana (canagliflozin) and Invokamet (canagliflozin and metformin), the US Food and Drug Administration (FDA) approved, last year an expanded indication for Invokamet [READ MORE]



READER COMMENTS

Posted by
henrymiller
on
diabetes medications ' glipizide ' chronic kidney disease lost toes then legs

Posted by
DON JOHNSON
on
I HAVE BEEN TAKING INVOKANA FOR ABOUT FOUR MONTHS,THE FIRST MONTH WAS GREAT BLOOD SUGARS REALY LOW. THEN IT STOPED WORKING AT ALL, NOW I CAN'T GET THEM DOWN AT ALL ,I TAKE A LOT OF INSULAN AND I JUST CHEKED ABOUT AN HOUR AGO AND WAS 456, I CAN'T IMAGINE WATS GOING ON.

ADD YOUR COMMENT ON THIS ISSUE

Fields marked * are mandatory. Please read our comment guidelines before posting.

*Name:

Note: Your name will be published with your comment.

*Email Address:

Your email will only be used if a response is needed.

*Your Comment:

Are you the defendant or a subject matter expert on this topic with an opposing viewpoint? We'd love to hear your comments here as well, or if you'd like to contact us for an interview please submit your details here.